Research Papers:

HMGA2 enhances 5-fluorouracil chemoresistance in colorectal cancer via the Dvl2/Wnt pathway

Xi Xu _, Yunfeng Wang, Hong Deng, Chungang Liu, Jingjing Wu and Maode Lai

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2018; 9:9963-9974. https://doi.org/10.18632/oncotarget.24133

Metrics: PDF 1581 views  |   HTML 2369 views  |   ?  


Xi Xu1,2, Yunfeng Wang3, Hong Deng1,2, Chungang Liu1,2,4, Jingjing Wu1,2 and Maode Lai1,2

1Department of Pathology, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310058, China

2Key Laboratory of Disease Proteomics of Zhejiang Province, Hangzhou, Zhejiang, 310058, China

3College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang, 150081, China

4Center of Biological Therapy, Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China

Correspondence to:

Maode Lai, email: [email protected]

Jingjing Wu, email: [email protected]

Keywords: HMGA2; Dvl2; 5-FU; chemoresistance; colorectal cancer

Received: July 12, 2017     Accepted: December 03, 2017     Published: January 10, 2018


Drug resistance is one of the main hurdles to overcome for the improvement of cancer patient survival. However, the underlying mechanisms remain largely unknown, and therapeutic options are limited. Here, we demonstrate a strong correlation between HMGA2 expression and chemosensitivity to 5-fluorouracil (5-FU), a widely used first-line systemic chemotherapy regimen for colorectal cancer (CRC) patients. Overexpression of HMGA2 enhances chemoresistance to 5-FU of CRC both in vitro and in vivo. Further experiments indicate that HMGA2 directly binds to the promoter of Dvl2 and induces its transcription, which leads to increased activation of the Wnt/β-catenin pathway. Taken together, our data suggest that HMGA2 enhances the chemoresistance to 5-FU in CRC via activating the Dvl2/Wnt pathway. Therefore, HMGA2 may serve as a predictive biomarker and a potential therapeutic target in CRC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24133